A Phase 1 Clinical Trial to Evaluate Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib
Phase of Trial: Phase I
Latest Information Update: 29 Apr 2017
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 27 Jun 2016 Status changed from not yet recruiting to recruiting.
- 24 May 2016 Planned End Date changed from 1 Feb 2018 to 1 Nov 2018.
- 24 May 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Nov 2017.